PathoQuest, announced that it has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM). PathoQuest is the first company in France to receive such a certificate from the ANSM for NGS viral safety testing. (“high-throughput sequencing detection of incidental replicative virus test in eukaryote cells”).
Press ReleasePARIS, FRANCE – September 25, 2018 — PathoQuest, a genomic expert dedicated to the microbiology testing market, the leader in clinical diagnostics and biologics testing applications, today announced the appointment of Christiane Honisch, Ph.D. as an...
PathoQuest announces enrollment of first patient in IDENTIFY, a prospective clinical study assessing the medico-economic benefit of iDTECT™ Blood for the diagnosis of bloodstream infection in immunocompromised patients
Press ReleasePARIS, FRANCE, May 22, 2018 – PathoQuest, a genomic expert for biologics testing and a leader in improving pathogen identification in clinical biological samples, today announced the initiation and enrollment of the first patient in a medico-economic...
Charles River Laboratories International, Inc. (NYSE: CRL) and PathoQuest today announced an expansion of their strategic partnership agreement to provide next generation sequencing (NGS) services to the biologics industry. As part of the expanded partnership, Charles River intends to make a direct investment in PathoQuest.